Results 191 to 200 of about 44,698 (259)

Precision immuno-oncology in oral cancer: latest trends in biomarkers, novel drug development and nanoparticle-based therapeutic platforms. [PDF]

Front Cell Dev Biol
Augustine D, Sowmya SV, Pushpalatha C, Prasad K, Khatoon H.   +4 more
europepmc   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Does immunotherapy hold great promise in endometrial cancer care? [PDF]

Front Immunol
Braszka M, Chowaniec H, Borowczyk M, Dwojak E, Stępień M, Ślubowska A, Mielczarek M, Markiewicz H, Ałtyn R, Zieliński P, Czerniak J, Adamczak O, Kluk A, Dworacki G, Dobosz P.   +14 more
europepmc   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Targeting metabolic reprogramming to enhance adoptive immunotherapy: emerging mechanisms and translational perspectives. [PDF]

J Transl Med
Yang L, Zhang C, Zhang Z, Yao S, Shen J, Zhang Z, Xiao Z, Wang S, Wu Z.   +8 more
europepmc   +1 more source

Organoid models for T cell-based immunotherapy in hepatobiliary cancers. [PDF]

Hepatobiliary Surg Nutr
Du L, Dong J, Du S.
europepmc   +1 more source

Designing universal T cell therapies: strategies to evade natural killer cells. [PDF]

Front Immunol
Bushara O, Linette GP, Carreno BM.
europepmc   +1 more source

Progress in cell-based immunotherapies for solid tumors. [PDF]

Discov Oncol
Zhang L, Zhang D, Wang B.
europepmc   +1 more source

Reprogramming adoptive cell therapy for osteosarcoma: engineering, vaccination, and tumor microenvironment remodeling. [PDF]

Front Immunol
Zuo S, Cheng N, Hou Z, Yang Y, Tian Q, Xu Y.   +5 more
europepmc   +1 more source